3-苄基-1-甲基哌啶 | 85237-73-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-苄基-1-甲基哌啶
• 英文名称: 3-benzyl-N-methylpiperidine
• 英文别名: 3-benzyl-1-methyl-piperidine；3-Benzyl-1-methyl-piperidin；3-Benzyl-1-methylpiperidine
• CAS: 85237-73-6
• 化学式: C₁₃H₁₉N
• 分子量: 189.301
• InChiKey: KTGLLSVNOMWZTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 、 铂 作用下， 生成 3-苄基-1-甲基哌啶
  参考文献：
  名称：

  Schoepf et al., Justus Liebigs Annalen der Chemie, 1958, vol. 616, p. 151,153, 157

  摘要：

  DOI：

文献信息

• Ruthenium(<scp>ii</scp>) and iridium(<scp>iii</scp>) complexes featuring NHC–sulfonate chelate
  作者：A. Rajaraman、A. R. Sahoo、F. Hild、C. Fischmeister、M. Achard、C. Bruneau

  DOI：10.1039/c5dt02867a

  日期：——

  Three new complexes bearing a chelating (κ²C,O) NHC-SO₃ ligand have been prepared.

  三个新的配合物，带有螯合（κ2C,O）NHC-SO3配体，已经被制备。
• N-heterocyclic carbene based ruthenium complexes for selective β-C(sp3)-H functionalization of N-fused saturated cyclic amines
  作者：Nazan Kaloğlu

  DOI：10.1016/j.tet.2018.12.049

  日期：2019.4

  Herein, a series of new ruthenium(II) complexes with the general molecular formula [RuCl2(arene)(NHC)], (arene = η6-p-cymene, NHC = N-heterocyclic carbene) were synthesized from in situ prepared silver(I)-NHCs by the transmetallation method. These complexes were fully characterized by analytical and spectral methods. Ruthenium(II) complexes were tested as promising catalyst for selective β-C(sp3)-H

  在本文中，与一般分子式将[RuCl了一系列新的钌（II）络合物2（芳烃）（NHC）]，（芳烃=  η 6 - p -cymene，NHC = Ñ -杂环卡宾）从合成原位制备通过过渡金属化法制备银（I）-NHC。这些配合物已通过分析和光谱方法进行了全面表征。钌（II）配合物被测试为在外部酸性添加剂存在下通过氢转移将N-甲基哌啶与各种醛选择性进行β-C（sp 3）-H官能化的有前途的催化剂。这些环保的交叉脱氢偶联剂可以生产C（3）-烷基化的N-不带烯胺的-甲基哌啶衍生物，仅二氧化碳和水为良性副产物。
• Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same
  申请人：Kim Seon Mi

  公开号：US20130137661A1

  公开（公告）日：2013-05-30

  Disclosed are compounds useful as gonadotrophin-releasing hormone (“GnRH”) receptor antagonist.

  披露了作为促性腺激素释放激素（“GnRH”）受体拮抗剂有用的化合物。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：MEDICAL RES COUNCIL TECHNOLOGY

  公开号：WO2010106333A1

  公开（公告）日：2010-09-23

  A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein R1 is selected from: aryl; heteroaryl; -NHR3; fused aryl-C4-7-heterocycloalkyI; -CONR4R5; -NHCOR6; -C3-7-cycloalkyl; -O-C3-7-cycloalkyl; -NR3R6; and optionally substituted -C1-6 alkyl; wherein said aryl, heteroaryl, fused aryl-C4-7-heterocycloalkyl and C4-7-heterocycloalkyl are each optionally substituted; R2 is selected from hydrogen, aryl, C1-6-alkyl, C2-6-alkenyl, C3-7-cycloalkyl, heteroaryl, C4-7 heterocycloalkyl and halogen, wherein said C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl and C4-7-heterocycloalkyl are each optionally substituted. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formula (I).

  一种具有式（I）的化合物，或其药学上可接受的盐或酯，其中R1选自：芳基；杂环芳基；-NHR3；融合芳基-C4-7-杂环烷基；-CONR4R5；-NHCOR6；-C3-7-环烷基；-O-C3-7-环烷基；-NR3R6；和可选择地取代的-C1-6烷基；其中所述的芳基、杂环芳基、融合芳基-C4-7-杂环烷基和C4-7-杂环烷基均可选择地取代；R2选自氢、芳基、C1-6-烷基、C2-6-烯基、C3-7-环烷基、杂环芳基、C4-7-杂环烷基和卤素，其中所述的C1-6-烷基、C2-6-烯基、芳基、杂环芳基和C4-7-杂环烷基均可选择地取代。进一步涉及制备具有式（I）的化合物的药物组合物、治疗用途和制备方法的其他方面。
• [EN] AMIDO-THIOPHENE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION
  申请人：UNIV EDINBURGH

  公开号：WO2009112845A1

  公开（公告）日：2009-09-17

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些酰胺-噻吩化合物，其中包括抑制11β-羟基类固醇脱氢酶1（11β-HSD1）的作用。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物和组合物，在体内和体外，抑制11β-羟基类固醇脱氢酶1；治疗通过抑制11β-羟基类固醇脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和心血管疾病，如缺血性（冠状）心脏病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。